ADOPTpilotNCT06698510
Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 6 words Show 7 more changesShow less
- Trial completed
- Final enrollment: 13118 participants (planned 18500)
- Primary completion date changed from estimate of Nov 2025 to Apr 1, 2025
- Study completion date changed from estimate of Mar 2026 to Oct 30, 2025
- Secondary endpoints: details revised at 1 of 1 entry
- Site details revised at 7 of 7 sites
- Collaborators revised (9)
- Minor Primary completion date: Jun 2025 to Nov 2025
- Study completion date: Jan 2026 to Mar 2026
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Nov 2024 to Nov 25, 2024
- Site details revised at 7 of 7 sites
- Collaborators revised (9)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
Preschool-aged children (24 to 59 months of age) of villages preselected to receive a single oral dose of 50mg/kg or 60mg/kg (depending on country) arpraziquantel as part of the routine schistosomiasis mass drug administration campaigns led by the national NTD programmes.
Preschool-aged children (24 to 59 months of age) of villages preselected to receive a single oral dose of 50mg/kg or 60mg/kg (depending on country) arpraziquantel as part of the routine vitamin A distribution/child health days campaigns led by the national nutrition programmes.
Drugs: Arpraziquantel 150mg dispersible tablet
Sites
7 sites in 3 countries
Côte d’Ivoire 3, Kenya 2, Uganda 2